Nothing Special   »   [go: up one dir, main page]

PE20181013A1 - Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3 - Google Patents

Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3

Info

Publication number
PE20181013A1
PE20181013A1 PE2018000150A PE2018000150A PE20181013A1 PE 20181013 A1 PE20181013 A1 PE 20181013A1 PE 2018000150 A PE2018000150 A PE 2018000150A PE 2018000150 A PE2018000150 A PE 2018000150A PE 20181013 A1 PE20181013 A1 PE 20181013A1
Authority
PE
Peru
Prior art keywords
antibody construct
bispecific antibody
antibody constructs
polynucleotide
egfrviii
Prior art date
Application number
PE2018000150A
Other languages
English (en)
Inventor
Tobias Raum
Peter Kufer
Doris Rau
Markus Muenz
Ines Herrmann
Patrick Hoffmann
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of PE20181013A1 publication Critical patent/PE20181013A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a un constructo de anticuerpo biespecifico que comprende un primer dominio de union que se une a EGFRVIII humano en la superficie de una celula diana y un segundo dominio de union que se une a CD3 humano en la superficie de una celula T. Ademas, la invencion provee un polinucleotido que codifica el constructo de anticuerpo, un vector que comprende dicho polinucleotido y una celula hospedante transformada o transfectada con dicho polinucleotido o vector. Adicionalmente, la invencion provee un procedimiento para la produccion del constructo de anticuerpo de la invencion, un uso medico de dicho constructo de anticuerpo y un kit que comprende dicho constructo de anticuerpo.
PE2018000150A 2015-07-31 2016-08-01 Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3 PE20181013A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199945P 2015-07-31 2015-07-31
US201662290861P 2016-02-03 2016-02-03

Publications (1)

Publication Number Publication Date
PE20181013A1 true PE20181013A1 (es) 2018-06-26

Family

ID=56800255

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000150A PE20181013A1 (es) 2015-07-31 2016-08-01 Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3

Country Status (32)

Country Link
US (3) US10519241B2 (es)
EP (2) EP3912999A1 (es)
JP (1) JP6986008B2 (es)
KR (1) KR20180034430A (es)
CN (1) CN107922495B (es)
AU (2) AU2016302683B2 (es)
BR (1) BR112018001374A2 (es)
CA (1) CA2991278C (es)
CL (1) CL2018000263A1 (es)
CO (1) CO2018000887A2 (es)
CR (1) CR20180065A (es)
CY (1) CY1124384T1 (es)
DK (1) DK3328892T3 (es)
ES (1) ES2876348T3 (es)
HK (1) HK1249523A1 (es)
HU (1) HUE054384T2 (es)
IL (1) IL256872B2 (es)
JO (1) JO3788B1 (es)
LT (1) LT3328892T (es)
MX (1) MX2018001161A (es)
MY (1) MY185953A (es)
PE (1) PE20181013A1 (es)
PH (1) PH12018500156A1 (es)
PL (1) PL3328892T3 (es)
PT (1) PT3328892T (es)
SG (1) SG10202109625YA (es)
SI (1) SI3328892T1 (es)
TN (1) TN2017000548A1 (es)
TW (1) TWI744242B (es)
UA (1) UA124417C2 (es)
WO (1) WO2017021370A1 (es)
ZA (1) ZA201708306B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009299791B2 (en) * 2008-10-01 2016-02-25 Amgen Research (Munich) Gmbh Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
CA2956471A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
CN109219618B (zh) 2016-01-21 2022-08-09 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
MY192474A (en) 2016-01-21 2022-08-23 Pfizer Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
MY195542A (en) 2016-02-03 2023-01-31 Amgen Res Munich Gmbh Psma and CD3 Bispecific T Cell Engaging Antibody Constructs
TN2018000263A1 (en) 2016-02-03 2020-01-16 Amgen Inc BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
ES2975221T3 (es) 2017-08-03 2024-07-04 Amgen Inc Muteínas de interleucina-21 y métodos de tratamiento
CA3075046A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
SG11202005605SA (en) 2018-01-12 2020-07-29 Amgen Inc Anti-pd-1 antibodies and methods of treatment
CA3096200A1 (en) * 2018-04-06 2019-10-10 The Regents Of The University Of California Trans-antigen targeting in heterogeneous cancers and methods of use thereof
BR112021002032A2 (pt) * 2018-08-03 2021-07-20 Amgen Research (Munich) Gmbh construtos de anticorpos para cldn18.2 e cd3
US20220242953A1 (en) * 2018-12-07 2022-08-04 Jiangsu Hengrui Medicine Co., Ltd. Cd3 antibody and pharmaceutical use thereof
CN113621062B (zh) * 2018-12-21 2024-07-02 豪夫迈·罗氏有限公司 与cd3结合的抗体
JP7090780B2 (ja) * 2018-12-21 2022-06-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ３に結合する抗体
EP4055061A4 (en) * 2019-11-07 2023-12-20 Amgen Inc. DOSAGE SCHEME FOR ANTI-EGFRVIII ACTIVE INGREDIENTS
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
CA3194762A1 (en) * 2020-09-11 2022-03-17 Amgen Inc. Materials and methods to reduce protein aggregation
JP2023550148A (ja) 2020-11-20 2023-11-30 シンシア・イノベーション・インコーポレイテッド がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法
AU2022365116A1 (en) * 2021-10-15 2024-05-02 Amgen Inc. Activatable polypeptide complex
WO2024067222A1 (en) * 2022-09-30 2024-04-04 Nona Biosciences (Suzhou) Co., Ltd. Cd3-targeting antibody and use thereof

Family Cites Families (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
KR970008597B1 (ko) 1987-12-28 1997-05-27 닛뽄 세키유가가쿠 가부시키가이샤 열가소성수지 조성물의 제조방법
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69131780T2 (de) 1991-03-11 2000-11-16 University Of Georgia Research Foundation, Athens Klonierung und expression der luziferase aus renilla
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
WO1994000569A1 (en) 1992-06-18 1994-01-06 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP0672141B1 (en) 1992-10-23 2003-05-14 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
NZ314644A (en) 1993-05-24 2000-11-24 Immunex Corp Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
US7045128B2 (en) 1993-05-24 2006-05-16 Immunex Corporation Antibodies against flt3-ligand
AU694745B2 (en) 1993-09-10 1998-07-30 Trustees Of Columbia University In The City Of New York, The Uses of green fluorescent protein
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
CN101333516A (zh) 1995-08-29 2008-12-31 麒麟医药株式会社 嵌合体动物及其制备方法
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
CA2271717A1 (en) 1996-12-12 1998-06-18 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6232107B1 (en) 1998-03-27 2001-05-15 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
SK286683B6 (sk) * 1998-04-21 2009-03-05 Micromet Ag Polypeptidy špecifické pre CD19xCD3 a ich použitie
DK1100830T3 (da) 1998-07-28 2004-01-19 Micromet Ag Heterominiantistoffer
US7254167B2 (en) 1998-10-30 2007-08-07 Broadcom Corporation Constellation-multiplexed transmitter and receiver
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
ES2645698T3 (es) 2001-11-30 2017-12-07 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
US8486859B2 (en) 2002-05-15 2013-07-16 Bioenergy, Inc. Use of ribose to enhance plant growth
US7904068B2 (en) 2003-06-06 2011-03-08 At&T Intellectual Property I, L.P. System and method for providing integrated voice and data services utilizing wired cordless access with unlicensed spectrum and wired access with licensed spectrum
EP1638606B1 (en) * 2003-06-27 2016-01-06 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
KR100995031B1 (ko) 2003-10-01 2010-11-19 엘지전자 주식회사 다중입력 다중출력 시스템에 적용되는 신호 전송 제어 방법
CA2540703C (en) 2003-10-03 2014-04-08 Board Of Regents, University Of Texas System Methods and compositions for mycoplasma pneumoniae exotoxins
DK1673398T3 (da) 2003-10-16 2011-04-18 Micromet Ag Multispecifikke, deimmuniserede CD3-bindere
EP1703348B1 (en) 2005-03-14 2010-10-13 Omron Corporation Programmable controller system
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
US8234145B2 (en) 2005-07-12 2012-07-31 International Business Machines Corporation Automatic computation of validation metrics for global logistics processes
BRPI0604215A (pt) 2005-08-17 2007-04-10 Biosigma Sa método para projetar oligonucleotìdeos para técnicas de biologia molecular
ES2616316T3 (es) * 2005-10-11 2017-06-12 Amgen Research (Munich) Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies y usos de los mismos
JP2007122396A (ja) 2005-10-27 2007-05-17 Hitachi Ltd ディスクアレイ装置及びその障害対応検証方法
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
US7919297B2 (en) 2006-02-21 2011-04-05 Cornell Research Foundation, Inc. Mutants of Aspergillus niger PhyA phytase and Aspergillus fumigatus phytase
US7574748B2 (en) 2006-03-07 2009-08-18 Nike, Inc. Glove with support system
NZ572745A (en) 2006-04-21 2010-05-28 Fountainhead Llc Buoyant wetland system
US7990860B2 (en) 2006-06-16 2011-08-02 Harris Corporation Method and system for rule-based sequencing for QoS
US8430938B1 (en) 2006-07-13 2013-04-30 The United States Of America As Represented By The Secretary Of The Navy Control algorithm for autothermal reformer
KR101146588B1 (ko) 2006-08-11 2012-05-16 삼성전자주식회사 Ｆｉｎ 구조체 및 이를 이용한 핀 트랜지스터의 제조방법
US7889507B2 (en) 2006-08-30 2011-02-15 Nec Corporation Portable apparatus
GB0618329D0 (en) 2006-09-18 2006-10-25 Ykk Europ Ltd Slider for fluid tight slide fastener
CN100589507C (zh) 2006-10-30 2010-02-10 华为技术有限公司 一种拨号提示系统及方法
US7466008B2 (en) 2007-03-13 2008-12-16 Taiwan Semiconductor Manufacturing Company, Ltd. BiCMOS performance enhancement by mechanical uniaxial strain and methods of manufacture
ES2553168T5 (es) 2007-03-30 2018-12-10 Vestas Wind Systems A/S Turbina eólica con control de paso
AU2008234020B2 (en) 2007-04-03 2013-02-07 Amgen Research (Munich) Gmbh Cross-species-specific CD3-epsilon binding domain
EP3461842A1 (en) * 2007-04-03 2019-04-03 Amgen Research (Munich) GmbH Cross-species-specific binding domain
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
US8209741B2 (en) 2007-09-17 2012-06-26 Microsoft Corporation Human performance in human interactive proofs using partial credit
US8464584B2 (en) 2007-10-19 2013-06-18 Food Equipment Technologies Company, Inc. Beverage dispenser with level measuring apparatus and display
DE102008057648A1 (de) 2007-11-29 2009-06-04 Luk Lamellen Und Kupplungsbau Beteiligungs Kg Kraftübertragungsvorrichtung, insbesondere zur Leistungsübertragung zwischen einer Antriebsmaschine und einem Abtrieb
EP2072971A1 (en) 2007-12-17 2009-06-24 Services Pétroliers Schlumberger Variable throat venturi flow meter
US8376279B2 (en) 2008-01-23 2013-02-19 Aurora Flight Sciences Corporation Inflatable folding wings for a very high altitude aircraft
AU2009237662A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US7922649B2 (en) 2008-08-08 2011-04-12 Walch John R Unitized penile erection system and tissue expander
US8053131B2 (en) 2008-08-14 2011-11-08 Hyundai Motor Company Apparatus and method for determining deterioration of a fuel cell and method for preventing deterioration of the same
KR101009644B1 (ko) 2008-08-26 2011-01-19 삼성모바일디스플레이주식회사 레이저 열전사용 도너 기판 및 이를 이용한 유기전계발광소자의 제조방법
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
WO2010101223A1 (ja) 2009-03-04 2010-09-10 日産自動車株式会社 排気ガス浄化触媒及びその製造方法
US8463191B2 (en) 2009-04-02 2013-06-11 Qualcomm Incorporated Beamforming options with partial channel knowledge
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
WO2011051489A2 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
JP5944831B2 (ja) 2009-12-23 2016-07-05 シュニムネ ゲーエムベーハーＳＹＮＩＭＭＵＮＥ ＧｍｂＨ 抗ｆｌｔ３抗体及びその使用方法
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
CN103347893A (zh) 2010-11-01 2013-10-09 诺维信生物制药丹麦公司 白蛋白变体
LT2637670T (lt) 2010-11-10 2017-05-25 Amgen Research (Munich) Gmbh Nepageidaujamų poveikių, kuriuos sukelia prisijungimo domenai specifiški cd3, prevencija
EP2647707B1 (en) 2010-11-30 2018-09-12 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
WO2012088461A2 (en) 2010-12-23 2012-06-28 Biogen Idec Inc. Linker peptides and polypeptides comprising same
KR20140027307A (ko) 2011-05-05 2014-03-06 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
CN103503396A (zh) 2011-05-10 2014-01-08 松下电器产业株式会社 振幅与正交度误差补偿装置
PL3321286T3 (pl) 2011-08-23 2021-05-31 Roche Glycart Ag Dwuswoiste cząsteczki wiążące antygen aktywujące limfocyty T
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
KR20140091064A (ko) 2011-11-16 2014-07-18 암젠 인크 표피 성장 인자 결실 돌연변이체 vⅲ 관련 장애를 치료하는 방법
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
JP6441079B2 (ja) 2011-12-19 2018-12-19 シンイミューン ゲーエムベーハー 二重特異性抗体分子
JP6407726B2 (ja) 2012-03-01 2018-10-24 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 長寿命ポリペプチド結合分子
BR112014018679A2 (pt) 2012-03-16 2017-07-04 Novozymes Biopharma Dk As variantes de albumina
EP2861619A4 (en) 2012-06-07 2016-01-27 Univ Duke HUMAN BISPECIFIC ANTIBODY MOLECULAR EGFRVII
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
JP2015528003A (ja) 2012-07-13 2015-09-24 ザイムワークス，インコーポレイテッド 抗ｃｄ３構築物を含む二重特異性の非対称ヘテロ二量体
JP6487328B2 (ja) 2012-11-08 2019-03-20 アルブミディクス リミティド アルブミン変異体
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
SG11201504497TA (en) 2013-02-26 2015-09-29 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2014138449A1 (en) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anti-c-met tandem fc bispecific antibodies
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
DK2970449T3 (da) 2013-03-15 2019-11-25 Amgen Res Munich Gmbh Enkeltkædede bindingsmolekyler, der omfatter n-terminal abp
EP3424952A1 (en) 2013-03-15 2019-01-09 Amgen, Inc Heterodimeric bispecific antibodies
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
EP3019532B1 (en) * 2013-07-09 2019-01-02 Duke University Human bispecific egfrviii antibody engaging molecules
DK3030581T3 (da) * 2013-08-07 2021-04-12 Affimed Gmbh Antistofbindingssteder, der er specifikke for egfrviii
EP3049440B1 (en) 2013-09-25 2020-03-25 Amgen Inc. V-c-fc-v-c antibody
UA120753C2 (uk) 2013-12-17 2020-02-10 Дженентек, Інк. Біспецифічне антитіло до сd3 та cd20
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
CA2956471A1 (en) * 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
ES2980787T3 (es) 2014-07-31 2024-10-03 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena sencilla biespecífico con distribución tisular potenciada
DK3608337T3 (da) 2014-08-04 2024-06-17 Hoffmann La Roche Bispecifikke T-celleaktiverende antigenbindende molekyler
JP2017529853A (ja) 2014-09-25 2017-10-12 アムジエン・インコーポレーテツド プロテアーゼにより活性化可能な二重特異性タンパク質
EP3928788A1 (en) 2014-11-26 2021-12-29 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
AU2016214978B2 (en) 2015-02-05 2021-12-09 The University Of Queensland Targeting constructs for delivery of payloads
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
US9552854B1 (en) * 2015-11-10 2017-01-24 Intel Corporation Register files including distributed capacitor circuit blocks
MY195542A (en) * 2016-02-03 2023-01-31 Amgen Res Munich Gmbh Psma and CD3 Bispecific T Cell Engaging Antibody Constructs
TN2018000263A1 (en) 2016-02-03 2020-01-16 Amgen Inc BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Also Published As

Publication number Publication date
MY185953A (en) 2021-06-14
IL256872B1 (en) 2023-12-01
MX2018001161A (es) 2018-05-23
JP6986008B2 (ja) 2021-12-22
JO3788B1 (ar) 2021-01-31
SG10202109625YA (en) 2021-10-28
ZA201708306B (en) 2020-01-29
US10519241B2 (en) 2019-12-31
AU2016302683B2 (en) 2022-09-29
IL256872A (en) 2018-03-29
PH12018500156A1 (en) 2018-07-23
DK3328892T3 (da) 2021-06-14
US20220064308A1 (en) 2022-03-03
KR20180034430A (ko) 2018-04-04
SI3328892T1 (sl) 2021-08-31
EP3912999A1 (en) 2021-11-24
EP3328892B1 (en) 2021-03-31
EP3328892A1 (en) 2018-06-06
TN2017000548A1 (en) 2019-04-12
CL2018000263A1 (es) 2018-10-05
US20200140558A1 (en) 2020-05-07
TW201716441A (zh) 2017-05-16
CA2991278A1 (en) 2017-02-09
WO2017021370A1 (en) 2017-02-09
AU2016302683A1 (en) 2018-01-04
LT3328892T (lt) 2021-06-10
CO2018000887A2 (es) 2018-04-19
UA124417C2 (uk) 2021-09-15
CN107922495B (zh) 2022-05-10
TWI744242B (zh) 2021-11-01
BR112018001374A2 (pt) 2018-09-11
CR20180065A (es) 2018-05-29
JP2018524997A (ja) 2018-09-06
ES2876348T3 (es) 2021-11-12
CY1124384T1 (el) 2022-07-22
PT3328892T (pt) 2021-06-14
CN107922495A (zh) 2018-04-17
AU2022291524A1 (en) 2023-02-02
HK1249523A1 (zh) 2018-11-02
HUE054384T2 (hu) 2021-09-28
IL256872B2 (en) 2024-04-01
US11155629B2 (en) 2021-10-26
PL3328892T3 (pl) 2021-09-27
CA2991278C (en) 2024-02-13
US20170029512A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
PE20181013A1 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
CL2021000717A1 (es) Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018
CL2020003416A1 (es) Constructos de anticuerpo biespecificos que se unen a mesotelina y cd3 (divisional sol. 201800268)
CL2021000716A1 (es) Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269)
CO2018000877A2 (es) Constructos de anticuerpo biespecificos que se unen a dll3 y cd3
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
CL2017002641A1 (es) Construcciones de anticuerpos biespecíficos contra cdh3 y cd3
MX2021008367A (es) Constructos de anticuerpos para cdh19 y cd3.
AR105558A1 (es) Constructos de anticuerpo para dll3 y cd3
AR105559A1 (es) Constructos de anticuerpo para cd70 y cd3
AR105560A1 (es) Constructos de anticuerpo para msln y cd3
AR105562A1 (es) Constructos de anticuerpo para receptor del factor de crecimiento epidérmico variante viii (egfrviii) y el antígeno cd3
AR105561A1 (es) Constructos de anticuerpo para el receptor de la tirosina quinasa (flt3) y el antígeno cd3